Subject plans to undergo current index PGx testing at the time of enrollment or underwent current index PGx testing within the prior 1-year period, for genes known to influence metabolism of at least one target drug
Subject is aged ≥18 years
Subject is able and willing to provide written informed consent
Subject reveals a history of at least one TDAE or an inadequate therapeutic effect from a target drug over the 12-month period preceding expected receipt of PGx test results
Subject is not taking an investigational medication or in an interventional trial that would interfere with participation in the registry
You may not be if
Subject is currently hospitalized
Subject's medical and medication history is unavailable over the 90-day periods preceding and following the receipt of pharmacogenomic test results
Subject is unable to provide an accurate history due to mental incapacity
Subject is known to have undergone prior pharmacogenomic testing (exclusive of the current index PGx testing) for genes specific to the target drugs within the 2-year period preceding enrollment and these results have been previously evaluated
